logo
Is Bulimia Different from Binge Eating?

Is Bulimia Different from Binge Eating?

Health Line10-06-2025
Bulimia nervosa and binge eating disorder (BED) are both serious eating disorders characterized by episodes of consuming large amounts of food, a behavior called binge eating.
The primary difference lies in the aftermath: people with bulimia engage in compensatory behaviors, such as vomiting or excessive exercise, to prevent weight gain, whereas those with BED don't often use such measures.
Whether you suspect you have BED, bulimia, or a different eating disorder, it's a good idea to seek help. These disorders are treatable. The first step is to speak with a healthcare professional.
Key similarities
Despite their differences, bulimia and BED share several characteristics:
Binge eating episodes: Both disorders involve consuming unusually large quantities of food in a specific period of time, accompanied by a sense of loss of control.
Emotional distress: People with these disorders often experience feelings of shame, guilt, or depression following binge episodes.
Triggers: Stress, negative emotions, or restrictive dieting can precipitate binge eating in both conditions.
Co-occurring mental health conditions: Both disorders are associated with higher rates of anxiety, depression, and other psychological conditions.
Co-occurring physical health conditions: Both BED and binge eating can lead to physical health issues.
Treatment: Both BED and bulimia are treatable. Therapy, lifestyle changes, and — in some cases — medications can help improve your symptoms.
Learn more about therapy for eating disorder treatment.
Because both BED and bulimia involve binge eating, many people confuse the two. A trained healthcare professional can help you find the correct eating disorder diagnosis and treat you accordingly.
Key differences
At first glance, bulimia and BED are quite similar. Understanding the distinctions between bulimia and BED is important for getting the right treatment.
Here are some key differences:
Compensatory behaviors: Unlike BED, bulimia involves trying to counteract the effects of binge eating, like self-induced vomiting, laxative misuse, fasting, or excessive exercise.
Prevalence: BED is more common than bulimia nervosa. In the US, about 1% of people will have bulimia at some point in their lives. For BED, that number rises to 2.8%.
Body weight: People with BED are more likely to be overweight or obese. People with bulimia may fall in a more 'normal' weight range, although this isn't always the case.
Body image: People with bulimia are more likely to have body image disturbances and an obsession with weight loss. However, people with BED may also have difficulties with body image.
Frequency: While both disorders involve binge eating, the frequencies can differ. BED is diagnosed if episodes occur at least once a week for three months without compensatory behaviors.
Health consequences: Bulimia can lead to electrolyte imbalances, gastrointestinal issues, and dental problems due to purging. BED is associated with obesity-related conditions like type 2 diabetes, hypertension, and cardiovascular disease.
If you think you have BED or bulimia, a healthcare professional can help you find a diagnosis and get the treatment you need.
When to contact a healthcare professional
If you or someone you know exhibits signs of bulimia or BED, it's essential to seek professional help. Early intervention can prevent complications and improve outcomes.
Consider reaching out to a healthcare professional if you experience any of the following symptoms:
Frequent episodes of eating large amounts of food in a short time
Engaging in purging behaviors or excessive exercise after eating
Feelings of distress, shame, or guilt related to eating habits
Preoccupation with body weight or shape
A medical professional specializing in can provide a comprehensive assessment and recommend appropriate treatment options.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings
Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings

Yahoo

time19 minutes ago

  • Yahoo

Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings

July 22 - UnitedHealth Group (NYSE:UNH) has tumbled roughly 42% year?to?date, driven by rising Medicare Advantage costs, a surprise CEO exit, withdrawn guidance and a Department of Justice probe. However, ahead of its July 29 Q2 earnings, Bernstein analyst Lance Wilkes tapped UNH as a 'Top Pick,' saying the pullback creates an attractive entry point. He noted the stock trades at about 13.5 times forward earnings, below its ten?year average. Warning! GuruFocus has detected 4 Warning Sign with UNH. Wilkes cut his 2025 EPS estimate by 10% to reflect reserve strengthening and cost pressures in individual and Medicaid segments, plus a cleanup of OptumHealth risk contracts. Yet he projects earnings per share could double by 2029, implying a 19% compound annual growth rate. The analyst expects cost normalization to begin in Medicaid in Q3 and in Medicare Advantage in early 2026 as utilization patterns stabilize. He also highlighted a hardening pricing environment for government managed?care plans as a margin tailwind. Is UNH Stock a Buy? Based on the one year price targets offered by 24 analysts, the average target price for UnitedHealth Group Inc is $375.46 with a high estimate of $677.00 and a low estimate of $270.00. The average target implies a upside of +33.08% from the current price of $282.14. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025
Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025

Yahoo

time19 minutes ago

  • Yahoo

Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025

MINNEAPOLIS, July 22, 2025--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) will release its fiscal second quarter results through June 28, 2025, before market open on Wednesday, July 30, 2025. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number is a sleep wellness company. We are guided by our purpose to improve the health and wellbeing of society through higher quality sleep. To date, our innovations have improved nearly 16 million lives. Our sleep wellness platform helps solve sleep problems, whether it's providing individualized temperature control for each sleeper through our Climate360 smart bed or applying our 34 billion hours of longitudinal sleep data and expertise to research with global institutions. Our smart bed ecosystem helps people sleep better by offering adjustable comfort and personalized sleep and health insights. Millions of Smart Sleepers benefit from higher quality sleep, and our 3,400 dedicated team members are passionate about creating innovative solutions through our vertically integrated business model, including direct-to-consumer selling in 630 stores and online. To learn more about life-changing, individualized sleep, visit a Sleep Number® store near you, our newsroom and investor relations sites, or View source version on Contacts Investor Contact investorrelations@ Media Contact Muriel Lussier, Sleep Number Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

Yahoo

time19 minutes ago

  • Yahoo

Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

– Video webcast now available on-demand SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio'), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Senti Bio Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships. Availability of Other Information About Senti Biosciences, Inc. For more information, please visit the Senti Bio website at or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website ( including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store